Current Report Filing (8-k)
October 11 2017 - 12:35PM
Edgar (US Regulatory)
UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
FORM 8-K
CURRENT REPORT
Pursuant to Section 13 or 15(d) of
The Securities Exchange Act of 1934
Date of Report (Date of Earliest Event Reported):
October
9, 2017
Commission File No. 000-16929
Soligenix, Inc.
(Exact name of small business issuer as specified
in its charter)
DELAWARE
|
|
41-1505029
|
(State or other jurisdiction of
incorporation or organization)
|
|
(I.R.S. Employer
Identification Number)
|
|
|
|
29 Emmons Drive,
Suite C-10
Princeton, NJ
|
|
08540
|
(Address of principal executive offices)
|
|
(Zip Code)
|
(609) 538-8200
|
(Issuer’s telephone number, including area code)
|
Check the appropriate box below if the Form
8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions
(see General Instruction A.2. below):
☐
Written
communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
☐
Soliciting
material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
☐
Pre-commencement
communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
☐
Pre-commencement
communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))
Indicate by check mark whether the registrant
is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2
of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).
Emerging growth company
o
If an emerging growth company, indicate by
check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial
accounting standards provided pursuant to Section 13(a) of the Exchange Act.
o
Item 7.01 Regulation
FD Disclosure.
On October 9, 2017, Soligenix,
Inc. (the “Company”) made a previously announced presentation regarding the dusquetide (SGX94) technology platform
and its potential anti-inflammatory, tissue healing, anti-infective and anti-tumor action, including data from the recently completed
Phase 2 trial in oral mucositis, at the 2nd World Congress and Expo on Immunology. During the presentation, Dr. Oreola Donini,
the Company’s Chief Scientific Officer, discussed the potential role for innate immune modulation in oncology as well as
in tissue healing, inflammation and infection, specifically with respect to the role of p62/sequestosome-1 in the tumor cell itself
as well as in the tumor microenvironment. Dr. Donini further noted that data from a preclinical study of SGX94 and the Phase 2
clinical trial of SGX942 for the treatment of oral mucositis in head and neck cancer patients may support the proposition of a
potential role for innate immune modulation in the oncology space with respect to tumor resolution. An audio archive of the presentation
is available on the Company’s website at www.soligenix.com/investors.
The information set forth
in this Current Report on Form 8-K is being furnished pursuant to Item 7.01 of Form 8-K and shall not be deemed “filed”
for purposes of Section 18 of the Securities Exchange Act of 1934, as amended (the “Exchange Act”), or otherwise subject
to the liabilities of that section, nor shall it be deemed incorporated by reference into any of the Company’s filings under
the Securities Act of 1933, as amended, or the Exchange Act, whether made before or after the date hereof and regardless of any
general incorporation language in such filings, except to the extent expressly set forth by specific reference in such a filing.
The filing of this Current Report on Form 8-K shall not be deemed an admission as to the materiality of any information herein
that is required to be disclosed solely by reason of Regulation FD.
SIGNATURE
Pursuant to the requirements
of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned
hereunto duly authorized.
|
Soligenix, Inc.
|
|
|
October 11, 2017
|
By:
|
/s/ Christopher J. Schaber
|
|
|
Christopher J. Schaber, Ph.D.
|
|
|
President and Chief Executive Officer
|
|
|
(Principal Executive Officer)
|
Soligenix (NASDAQ:SNGX)
Historical Stock Chart
From Mar 2024 to Apr 2024
Soligenix (NASDAQ:SNGX)
Historical Stock Chart
From Apr 2023 to Apr 2024